News | January 18, 2021
Zydus eyes $6 bn market with strong COVID-19 portfolio
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
Veteran healthcare executive to drive international growth, strategic partnerships, and global commercialization of the company's molecular diagnostics portfolio
CEO Stéphane Bancel framed the changes as essential to scaling the business
The newly approved treatment, SKINVIVE by JUVÉDERM, is now the first and only hyaluronic acid injectable cleared specifically for improving neck appearance
Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
Generic launch targets a US$19 million market in United States, strengthening Glenmark’s institutional and injectable product portfolio in North America
Collaboration integrates MERCURIUS DRUG-seq technologies with Revvity’s screening portfolio, enabling scalable transcriptomic profiling for next-generation drug discovery and AI-driven research
Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing
New-generation cardiac ablation technology expands treatment options for atrial fibrillation patients, offering a non-thermal approach to improve safety and procedural efficiency
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
